Literature DB >> 28901003

Expression of TIM-3 and LAG-3 in extranodal NK/T cell lymphoma, nasal type.

Yuhua Feng1, Meizuo Zhong1, Yiping Liu1, Leyuan Wang2, Youhong Tang3.   

Abstract

OBJECTIVE: To investigate the expression of TIM-3 and LAG-3 in extranodal NK/T cell lymphoma, nasal type (ENKTL), and evaluate the clinical and prognostic significance of TIM-3 and LAG-3 in ENKTL.
METHODS: A total of 61 human paraffin-embedded specimens including 41 ENKTL and 20 rhinitis were involved. We performed immunohistochemistry to detect the expression of TIM-3 and LAG-3. We analyzed correlation between expression of TIM-3 and LAG-3 and clinicopathological features of ENKTL.
RESULTS: TIM-3 was positively expressed in 95 (39/41) ENKTL compared with 55% (11/20) in rhinitis, LAG-3 was positively expressed in 95 (39/41) ENKTL compared with 45% (9/20) in rhinitis. A positive correlation was found between TIM-3 and LAG-3. TIM-3 and LAG-3 had no significant correlation with ENKTL patients' age, gender, international prognostic index (IPI) score, B symptoms, LDH level, Ann Arbor stage and treatment regimens. High expression of TIM-3, high IPI score, elevated LDH level and late Ann Arbor stage were shown to be correlated with worse progression free survival (PFS). A multivariate COX regression model show that TIM-3 high expression rate was an independent prognostic factor for ENKTL patients' PFS.
CONCLUSIONS: Our findings indicate that TIM-3 might be a promising predictive indicator for the ENKTL patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28901003     DOI: 10.14670/HH-11-931

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  10 in total

1.  Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.

Authors:  Yang Zhao; Hui Xu; Mingzhi Zhang; Ling Li
Journal:  Front Genet       Date:  2022-05-04       Impact factor: 4.772

Review 2.  Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy.

Authors:  F Li; Y Chen; M Pang; P Yang; H Jing
Journal:  Clin Exp Immunol       Date:  2021-03-28       Impact factor: 5.732

Review 3.  Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.

Authors:  Xi Chen; Wanchun Wu; Wenwen Wei; Liqun Zou
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

4.  Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.

Authors:  Yangying Zhou; Zhijie Xu; Wei Lin; Yumei Duan; Can Lu; Wei Liu; Weiping Su; Yuanliang Yan; Huan Liu; Li Liu; Meizuo Zhong; Jianhua Zhou; Hong Zhu
Journal:  Front Oncol       Date:  2019-07-25       Impact factor: 6.244

5.  Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis.

Authors:  Ramy R Saleh; Paloma Peinado; Jesús Fuentes-Antrás; Pedro Pérez-Segura; Atanasio Pandiella; Eitan Amir; Alberto Ocaña
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

6.  [The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma].

Authors:  L Nie; X Y Liu; R J Ma; X L Yuan; L Jiang; J Yang; A X Hu; Z Li; Z M Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-07-14

Review 7.  Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges.

Authors:  Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Mol Ther Oncolytics       Date:  2021-11-29       Impact factor: 7.200

Review 8.  Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

9.  Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.

Authors:  Won Seog Kim; Yasuhiro Oki; Seok Jin Kim; Sang Eun Yoon; Kirit M Ardeshna; Yi Lin; Jia Ruan; Pierluigi Porcu; Jonathan E Brammer; Eric D Jacobsen; Dok Hyun Yoon; Cheolwon Suh; Felipe Suarez; John Radford; Lihua E Budde; Jin Seok Kim; Emmanuel Bachy; Hun Ju Lee; Catherine M Bollard; Arnaud Jaccard; Hye Jin Kang; Shannon Inman; Maryann Murray; Katherin E Combs; Daniel Y Lee; Ranjana Advani; Kurt C Gunter; Cliona M Rooney; Helen E Heslop
Journal:  Ann Hematol       Date:  2021-07-24       Impact factor: 3.673

10.  Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.

Authors:  Yangying Zhou; Wei Liu; Zhijie Xu; Hong Zhu; Desheng Xiao; Weiping Su; Ruolan Zeng; Yuhua Feng; Yumei Duan; Jianhua Zhou; Meizuo Zhong
Journal:  Neoplasia       Date:  2018-09-15       Impact factor: 5.715

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.